Clinical trials: Skin Stiffness
Degenerative Osteoarthritis, Rheumatoid Arthritis
Orthopilot Elite Post-Market Clinical Follow-Up
Prospective, multicenter, observational, comparative clinical trial on the equivalence of two different OrthoPilot® navigation system generations applied for computer-assisted total knee arthroplasty
- Conditions
- Degenerative Osteoarthritis, Rheumatoid Arthritis, Posttraumatic Arthropathy, Instability, Joint
- Trial name
- NCT03817632
- Testing
- Computer assisted primary total knee replacement with OrthoPilot FS101 navigation system and Software 5.1, Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0
- Where
- 3 sites in Germany
- Volunteers
- 217 people
- Sponsor
- Aesculap AG
Degenerative Osteoarthritis, Rheumatoid Arthritis
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Prospective, multinational pilot study for evaluation of the Pheno4U data platform in Total Knee Arthroplasty (TKA) patients
- Conditions
- Degenerative Osteoarthritis, Rheumatoid Arthritis, Posttraumatic Arthropathy, Chronic Instability of Knee
- Trial name
- Pheno4U Pilot (NCT05302934)
- Testing
- Pheno4U
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 600 people
- Sponsor
- Aesculap AG
Rheumatoid Arthritis
A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis
This 2 arm study will investigate the effects of tocilizumab on lipids, arterial stiffness, and markers of atherogenic risk in patients with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT00535782
- Testing
- Tocilizumab, Methotrexate
- Where
- 40 sites in United States, Canada and 2 more
- Volunteers
- 132 people
- Sponsor
- Hoffmann-La Roche
Degenerative Osteoarthritis, Rheumatoid Arthritis
All Polyethylene Tibia-VEGA Kiel
Obligatory Post-Marketing Clinical Follow-up (PMCF) as part of the post marketing surveillance plan for the product under investigation For this PMCF only CE-marked medical devices will be used within their intended purpose and…
- Conditions
- Degenerative Osteoarthritis, Rheumatoid Arthritis, Post-traumatic; Arthrosis, Other Instability, Knee
- Trial name
- APT-VEGA_KI (NCT02756702)
- Testing
- All-Poly
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Aesculap AG
Rheumatoid Arthritis
Efficacy of Lodotra®(Prednisone) in Reduction of Morning Stiffness Duration(K-IMPROvE)
This study is multicenter, Ph IV, single arm, interventional study to assess relative reduction of morning stiffness of Lodotra® in Rheumatoid Arthritis patients.Study medication will start after study visit at baseline (week 0…
- Trial name
- NCT02072200
- Testing
- Lodotra®
- Where
- South Korea
- Volunteers
- 147 people
- Sponsor
- Mundipharma Korea Ltd
Rheumatoid Arthritis
Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis
The objective of this study is to investigate if low doses of prednisone MR formulation, given at night and, with active drug release at 2 am, are more effective in controlling joint stiffness, and other disease symptoms of…
- Trial name
- NCT00146640
- Testing
- MR Prednisone, IR Prednisone
- Where
- 24 sites in Germany, Poland
- Volunteers
- 288 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Rheumatoid Arthritis
Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis
The goal of this randomised, double-blind, placebo-controlled Phase II clinical trial is to assess the safety and effect of of IHL-675A in rheumatoid arthritis patients on pain, and function according to RAPID-3.
- Trial name
- CHAPPII (NCT05942911)
- Testing
- IHL-675A, Cannabidiol, Hydroxychloroquine
- Where
- 10 sites in Australia
- Volunteers
- 20 people
- Sponsor
- Incannex Healthcare Ltd
Arthritis, Rheumatoid
Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World
This study will be conducted to observe the disease activity change of Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARD) plus anti-tumour necrosis factor (anti-TNF) from baseline to 6 months compared with cDMARDs, as…
- Trial name
- HUMAN (NCT03264703)
- Where
- 15 sites in South Korea
- Volunteers
- 212 people
- Sponsor
- Eisai Korea Inc.
Degenerative Osteoarthritis, Rheumatoid Arthritis
VEGA Prospective Kiel
Voluntary Post-Marketing Clinical Follow-up (PMCF) as part of the post marketing surveillance plan for the product under investigation.
- Trial name
- NCT02802085
- Testing
- VEGA Knee
- Where
- Germany
- Volunteers
- 84 people
- Sponsor
- Aesculap AG